| Cardiac implications for the use of beta(2)-adrenoceptor agonists for the management of muscle wasting (2006) | |||||||||||||
Abstract | |||||||||||||
| There are proposals for the implementation of beta(2)-adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that beta(2)-adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart beta(2)-adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients. | |||||||||||||
Publication details | |||||||||||||
| |||||||||||||